EMILY WIGGINS: Open Payments
NPI 1114705225 · TERRYTOWN, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$644 in 28 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $285 · 2025 $644
Food & beverage: $644
| Company | Payments | Amount |
|---|---|---|
| Travere Therapeutics, Inc. | 1 | $114 |
| Otsuka America Pharmaceutical, Inc. | 5 | $99 |
| Amgen Inc. | 4 | $86 |
| Fresenius USA Marketing, Inc. | 4 | $85 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $76 |
| AstraZeneca Pharmaceuticals LP | 4 | $75 |
| Novo Nordisk Inc | 2 | $36 |
| Vifor Pharma, Inc. | 2 | $36 |
| AKEBIA THERAPEUTICS INC | 1 | $20 |
| Calliditas Therapeutics US Inc. | 1 | $16 |
Products named: Filspari, TAVNEOS, VELPHORO, JYNARQUE, JARDIANCE, FARXIGA, Ozempic, Veltassa.
Industry payments across LA — which companies pay providers there.
